Las Vegas, NV -- (SBWIRE) -- 12/06/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: BioTelemetry Inc (NASDAQ:BEAT), JA Solar Holdings Co., Ltd. (ADR) (NASDAQ:JASO), Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), North American Palladium Ltd (USA) (NYSEMKT:PAL)
BioTelemetry Inc (NASDAQ:BEAT) managed to keep its fall at -12.40% on above-normal volume of 2.26M shares. The stock settled at $7.49 after floating in a range of $7.43 to $8.73. Its latest price has reached market capitalization of $192.91 million. Its 52-week range has been $2 to $11.88. BioTelemetry, Inc. (BioTelemetry), formerly CardioNet, Inc., provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Has BEAT Found The Bottom and Ready To Move Up? Find Out Here
JA Solar Holdings Co., Ltd. (ADR) (NASDAQ:JASO) traded down on a volume of 2.18 million, lower than its standard daily volume. Shares have dropped-2.64% to $9.23. Over the last twelve months, the stock has gained 147.79% and faced a worst price of $3.21. JA Solar Holdings Co., Ltd. (JA Solar) is engaged in the business of designing, developing, manufacturing and selling solar cell and solar module products.
Has JASO Found The Bottom And Ready To Gain Momentum? Find Out Here
Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) settled 0.51% higher at $1.98 on above-normal volume of 1.98M shares during the last trading day. The stock has its 12-month high at $3.65 and 52-week low price was $0.41. It traded in a range of $1.95 to $2.09 during the last trading day. Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy. As of December 31, 2011, the Company had two drugs in development: CPP-109 and CPP-115. of December 31, 2011, it was evaluating its drug candidate, CPP-109 for the treatment of cocaine addiction.
Why Should Investors Buy CPRX After the Recent Fall? Just Go Here and Find Out
In the last trading session, North American Palladium Ltd (USA) (NYSEMKT:PAL) was down on low volume, trading at a volume of 1.96M versus its average daily volume of 2 million shares. At $0.410, the stock has attained market capitalization of 80.68 million. North American Palladium Ltd. (NAP) is a precious metals producer that has been operating its flagship Lac des Iles mine (LDI) located in Ontario, Canada. LDI is a primary producer of palladium. The Company is in the business of exploring and mining palladium, platinum, gold and certain base metals. The Company’s 100%-owned subsidiary is the Lac des Iles Mines Ltd. (LDI).
Why Should Investors Buy PAL After the Recent Fall? Just Go Here and Find Out
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)